Insmed (NASDAQ:INSM) Price Target Lowered to $205.00 at Royal Bank Of Canada

Insmed (NASDAQ:INSM) had its price target reduced by Royal Bank Of Canada from $220.00 to $205.00 in a research report sent to investors on Friday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

INSM has been the topic of several other research reports. Leerink Partners lifted their target price on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research note on Tuesday, March 24th. Raymond James Financial initiated coverage on Insmed in a research note on Friday, April 10th. They set an “outperform” rating and a $200.00 target price on the stock. Guggenheim decreased their target price on Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a research note on Friday. Stifel Nicolaus lifted their target price on Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Barclays lifted their target price on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Insmed presently has an average rating of “Buy” and an average target price of $211.86.

Insmed Stock Down 3.6%

Shares of INSM opened at $101.17 on Friday. The business’s 50 day moving average is $145.87 and its 200 day moving average is $165.46. The company has a market capitalization of $21.84 billion, a PE ratio of -17.60 and a beta of 0.89. Insmed has a 12-month low of $64.85 and a 12-month high of $212.75. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative return on equity of 121.03% and a negative net margin of 144.44%.The firm’s quarterly revenue was up 229.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.42) EPS. Research analysts expect that Insmed will post -2.41 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 13,396 shares of Insmed stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $44,512,131.15. This trade represents a 4.26% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 174,589 shares of company stock worth $27,441,807. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in shares of Insmed in the 4th quarter worth approximately $27,000. Stone House Investment Management LLC purchased a new position in shares of Insmed in the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. boosted its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the period. Finally, GraniteShares Advisors LLC purchased a new position in Insmed during the 4th quarter valued at $30,000.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.